Acetaminophen Cuts Risk of Acute Kidney Injury After Cardiac Surgery
Acetaminophen may reduce the risk of cardiac surgery-associated acute kidney injury (AKI), which is tied with complications and early death.
Source: clinicaladvisor.com
Page 13 - Research Database News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Research Database. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Research Database Today - Breaking & Trending Today
Acetaminophen Cuts Risk of Acute Kidney Injury After Cardiac Surgery
Acetaminophen may reduce the risk of cardiac surgery-associated acute kidney injury (AKI), which is tied with complications and early death.
Source: renalandurologynews.com
Top 10 AI and machine learning stories of 2022
Efforts to harness artificial intelligence to streamline healthcare operations and improve patient outcomes accelerated this year, as providers strove to fine-tune algorithms and arrive at deeper insights into clinical and operational patterns.
Source: healthcareitnews.com
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
11.12.2022 - Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion ('vein-to-vein' time) for Yescarta ...
Source: wallstreet-online.de
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
– Kite’s Manufacturing Time for Yescarta® in the U.S. is Median of 7-Days from Start of Cell Enrichment to Harvest, with an Overall 16-Day Turnaround Time (Leukapheresis to Product Release) – – CIBMTR Analysis Finds Median ‘Vein-to-Vein’ Time (Leukapheresis to Infusion) in Real World Setting is 27-Days for Yescarta in the U.S. – – In Same Analysis, Shorter Vein-to-Vein Time Associated with 60% Complete Response Rate in Patients Treated with Yescarta at Median Follow-Up of 24.2 Months –
Source: marketscreener.com